Erik Plantiko
Physician Assistant · Onalaska, WANPI 1427661966
Payments from drug & device makers
Across 305 payments — averaging $15.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$995
- AbbVie$949
- Lilly USA, LLC$441
- Boehringer Ingelheim$360
- GSK$358
- AstraZeneca$247
- plus $1K from 21 others
What the payments were for
- Food & beverage$4,609100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 59 | $995 |
| AbbVie | 69 | $949 |
| Lilly USA, LLC | 38 | $441 |
| Boehringer Ingelheim | 23 | $360 |
| GSK | 22 | $358 |
| AstraZeneca | 12 | $247 |
| Amgen | 17 | $217 |
| Novartis | 9 | $134 |
| Pfizer | 7 | $123 |
| Sanofi-aventis U.S. LLC | 7 | $106 |
| Grifols USA, LLC | 5 | $101 |
| Astellas Pharma US Inc | 6 | $87 |
| Johnson & Johnson | 5 | $81 |
| Bayer | 4 | $55 |
| Amarin Pharma, Inc. | 4 | $51 |
| Kyowa Kirin, Inc. | 2 | $48 |
| Exact Sciences | 3 | $48 |
| Teva Pharmaceuticals USA, Inc. | 2 | $39 |
| Idorsia Pharmaceuticals US Inc | 2 | $33 |
| Ultragenyx Pharmaceutical Inc. | 2 | $27 |
| Organon | 1 | $19 |
| Dexcom, Inc. | 1 | $18 |
| Xeris Pharmaceuticals, Inc. | 1 | $16 |
| Mylan Specialty L.p. | 1 | $15 |
| Biohaven Pharmaceuticals, Inc. | 1 | $14 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $14 |
| Phathom Pharmaceuticals, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$124
How this compares
$4,609 in reported general payments places this provider in the 95th percentile of 2,741 physician assistant providers in Washington.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 96 | $129,232 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 100 | $98,369 |
| TrulicityDulaglutide | 42 | $63,926 |
| JardianceEmpagliflozin | 49 | $54,260 |
| FarxigaDapagliflozin Propanediol | 36 | $47,364 |
| EliquisApixaban | 27 | $40,190 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 47 | $39,336 |
| EntrestoSacubitril/Valsartan | 33 | $30,194 |
| RybelsusSemaglutide | 13 | $29,876 |
| XareltoRivaroxaban | 27 | $27,485 |
| MounjaroTirzepatide | 19 | $20,428 |
| Spiriva RespimatTiotropium Bromide | 30 | $19,858 |
| MyrbetriqMirabegron | 28 | $18,346 |
| BelsomraSuvorexant | 22 | $11,179 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 15 | $10,660 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $995 | $159,108109 claims |
| GSKTrelegy Ellipta | $358 | $98,369100 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat, Stiolto Respimat, Combivent Respimat | $360 | $95,356109 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $247 | $94,517113 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $441 | $84,35461 claims |
| PfizerEliquis | $123 | $40,19027 claims |
| NovartisEntresto | $134 | $30,19433 claims |
| Johnson & JohnsonXarelto | $81 | $27,48527 claims |
| Astellas Pharma US IncMyrbetriq | $87 | $18,34628 claims |
| AbbVieSynthroid | $949 | $2,21319 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,741 physician assistant providers in Washington.
Other physician assistant in Onalaska
- Jill KandoraShoreline$437K
- Jeannette HartRichland$263K
- Lance KeckTacoma$162K
- Erinn KingSeattle$129K
- Christy VathSeattle$75K
- Scott TaylorMercer Island$71K
- Gina FragioneGraham$69K
- Regan BrownSpokane$56K
- Justin ChapinSeattle$40K
- Susan DuffyBellevue$23K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.